立方制药(003020) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for the first quarter of 2021 was CNY 549,093,775.22, representing a 21.34% increase compared to CNY 452,514,094.49 in the same period last year[9]. - The net profit attributable to shareholders of the listed company reached CNY 41,691,278.46, a 43.59% increase from CNY 29,035,673.38 year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 40,065,652.84, marking a significant increase of 65.10% from CNY 24,267,266.02 in the previous year[9]. - The basic earnings per share for the first quarter was CNY 0.45, up 7.14% from CNY 0.42 in the same period last year[9]. - Total operating revenue for Q1 2021 was CNY 549,093,775.22, an increase of 21.4% compared to CNY 452,514,094.49 in Q1 2020[42]. - Net profit for Q1 2021 reached CNY 41,691,278.46, representing a 43.7% increase from CNY 29,035,673.38 in Q1 2020[44]. - The company reported a gross profit of CNY 215,832,650.89 for Q1 2021, reflecting a gross margin of approximately 39.2%[42]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,659,458,754.63, an increase of 8.04% from CNY 1,536,019,607.62 at the end of the previous year[9]. - The total liabilities as of March 31, 2021, were CNY 443,774,345.14, up from CNY 362,026,476.59 at the end of 2020, marking an increase of about 22.6%[36]. - The company's non-current assets totaled CNY 294,994,007.23, an increase from CNY 244,058,157.18, reflecting a growth of about 20.9%[35]. - The total equity increased to CNY 1,078,265,973.01 as of March 31, 2021, compared to CNY 1,039,920,682.68 at the end of 2020[41]. - The total current assets amounted to CNY 1,364,464,747.40, an increase from CNY 1,291,961,450.44 as of December 31, 2020, reflecting a growth of approximately 5.6%[34]. Cash Flow - The net cash flow from operating activities was CNY 7,347,550.03, a decrease of 56.91% compared to CNY 17,053,489.84 in the same period last year[9]. - Cash and cash equivalents decreased by 77.89% to ¥169,517,172.34 due to cash management activities[16]. - The cash flow from investment activities showed a net outflow of ¥594,926,964.59, significantly higher than the outflow of ¥10,090,168.99 in the previous period[53]. - The cash and cash equivalents at the end of the period were ¥125,564,084.28, down from ¥170,585,405.59 in the previous period, a decrease of about 26.4%[54]. Expenses - Total operating costs for Q1 2021 were CNY 500,968,799.74, up 19.7% from CNY 418,504,423.71 in the same period last year[42]. - Research and development expenses surged by 183.84% to ¥12,404,825.37, reflecting increased payments based on project progress[17]. - Financial expenses rose by 90.87% to -¥877,953.59, mainly due to increased interest income from deposits[18]. Other Financial Metrics - The company reported a government subsidy of CNY 608,718.15, which is closely related to its business operations[9]. - The company reported no overdue receivables or non-compliance with external guarantees during the reporting period, indicating a stable financial position[28]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period, ensuring financial integrity[29]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[42].